000120407 001__ 120407
000120407 005__ 20240228145443.0
000120407 0247_ $$2doi$$a10.1186/s12885-017-3113-z
000120407 0247_ $$2pmid$$apmid:28193188
000120407 0247_ $$2pmc$$apmc:PMC5307829
000120407 037__ $$aDKFZ-2017-00836
000120407 041__ $$aeng
000120407 082__ $$a610
000120407 1001_ $$0P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aLehners, Nicola$$b0$$eFirst author
000120407 245__ $$aAnalysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement.
000120407 260__ $$aLondon$$bBioMed Central$$c2017
000120407 3367_ $$2DRIVER$$aarticle
000120407 3367_ $$2DataCite$$aOutput Types/Journal article
000120407 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522324311_8698
000120407 3367_ $$2BibTeX$$aARTICLE
000120407 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120407 3367_ $$00$$2EndNote$$aJournal Article
000120407 520__ $$aSkeletal involvement (SI) is observed at low prevalence in patients with diffuse large B-cell lymphoma (DLBCL). Due to the rareness of this particular condition, prospective trials for these patients are scarce.We analyzed clinical characteristics and outcome of 75 patients with DLBCL and SI in order to identify factors with prognostic impact towards progression-free survival (PFS) and overall survival (OS).Limited stage disease (Ann Arbor stage IE-IIE) was present in 34 patients (45%), 41 patients (55%) had advanced stage disease (Ann Arbor stage IIIE-IVE). Outcome was generally favorable for patients with DLBCL and SI with 3-year OS of 83%. The international prognostic index (IPI) was able to distinguish between different risk groups within this specific entity. Additionally, hypercalcemia showed to be a factor significantly associated with inferior survival. In regard to first-line treatment modalities, consolidative radiotherapy was positively associated with prolonged PFS and OS while intensification of chemotherapy had no significant impact.In our cohort of patients with DLBCL and SI, high-risk IPI as well as presence of hypercalcemia were associated with inferior outcome. Consolidative radiotherapy had a positive impact on survival.
000120407 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000120407 588__ $$aDataset connected to CrossRef, PubMed,
000120407 7001_ $$aKrämer, Isabelle$$b1
000120407 7001_ $$0P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74$$aSaadati, Maral$$b2
000120407 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b3
000120407 7001_ $$aHo, Anthony D$$b4
000120407 7001_ $$aWitzens-Harig, Mathias$$b5
000120407 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-017-3113-z$$gVol. 17, no. 1, p. 128$$n1$$p128$$tBMC cancer$$v17$$x1471-2407$$y2017
000120407 909CO $$ooai:inrepo02.dkfz.de:120407$$pVDB
000120407 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8dc0876dc3ed1862337d98842984727d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120407 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120407 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000120407 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000120407 9141_ $$y2017
000120407 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2015
000120407 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120407 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120407 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120407 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000120407 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000120407 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000120407 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120407 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120407 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120407 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120407 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120407 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120407 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120407 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000120407 980__ $$ajournal
000120407 980__ $$aVDB
000120407 980__ $$aI:(DE-He78)C060-20160331
000120407 980__ $$aUNRESTRICTED